Literature DB >> 19391135

Estrogen regulation of thrombospondin-1 in human breast cancer cells.

Salman M Hyder1, Yayun Liang, Jianbo Wu.   

Abstract

Expression of thrombospondin-1 (TSP-1), a large extracellular matrix protein, has been associated with modulation of angiogenesis and tumor growth. Both pro and antiangiogenic properties of TSP-1 have been described, and the role of TSP-1 expression in the growth and progression of human breast cancer is not clear. Because estrogens cause progression of many breast cancers, and estradiol (E2) downregulates a TSP-1 receptor, we examined whether TSP-1 is regulated by estrogen and involved in tumor progression. E2 induced TSP-1 expression in T47-D and MCF-7 breast cancer cells in vitro within 3 to 6 hr; the induction was blocked by the anti-estrogen ICI 182,780, indicating that estrogen receptors (ER) are necessary for this effect. Furthermore, E2 caused the production of TSP-1 protein from tumor cells in an ER-alpha-dependent manner. The E2-mediated TSP-1 RNA induction was dose-dependent and blocked by actinomycin D, indicating that the response to E2 was at least partly transcriptional. Transfection studies with deletion constructs of the TSP-1 promoter identified an estrogen-responsive region in the human TSP-1 promoter, located between -2,200 and -1,792 bp upstream of the transcription start site. An antibody against TSP-1 restricted the proliferation of E2-dependent MCF-7 cells in vitro and in vivo. A panel of breast cancer cells proliferated in the presence of low concentrations of exogenous TSP-1, whereas higher concentrations inhibited proliferation. A real-time PCR analysis showed that E2 also induced TSP-1 mRNA in the normal mammary glands of immature ovariectomized mice in an ER-dependent manner. In summary, we report the novel observation that TSP-1 production is directly controlled by estrogens in ER-positive breast cancer cells, and the released protein has pro-growth regulatory functions. Consequently, we propose that TSP-1 could be a therapeutic target for anti-tumor therapy in early-stage tumors. (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19391135      PMCID: PMC2755594          DOI: 10.1002/ijc.24373

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

1.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia.

Authors:  N Bertin; P Clezardin; R Kubiak; L Frappart
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

2.  Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.

Authors:  T N Wang; X H Qian; M S Granick; M P Solomon; V L Rothman; D H Berger; G P Tuszynski
Journal:  Surgery       Date:  1996-08       Impact factor: 3.982

3.  Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.

Authors:  J Nakamura; A Savinov; Q Lu; A Brodie
Journal:  Endocrinology       Date:  1996-12       Impact factor: 4.736

Review 4.  Steroid hormone receptors in breast cancer management.

Authors:  C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

5.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

6.  Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice.

Authors:  Marie K Lindberg; Sofia Movérare; Stanko Skrtic; Hui Gao; Karin Dahlman-Wright; Jan-Ake Gustafsson; Claes Ohlsson
Journal:  Mol Endocrinol       Date:  2003-02

7.  Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice.

Authors:  M F El Etreby; Y Liang
Journal:  Breast Cancer Res Treat       Date:  1998-05       Impact factor: 4.872

8.  Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.

Authors:  Katsumi Motegi; Koji Harada; Sima Pazouki; Robin Baillie; Ana M Schor
Journal:  Histochem J       Date:  2002 Aug-Sep

9.  Thrombospondin levels in patients with malignancy.

Authors:  G P Tuszynski; M Smith; V L Rothman; D M Capuzzi; R R Joseph; J Katz; E C Besa; J Treat; H I Switalska
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

10.  Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta.

Authors:  A RayChaudhury; W A Frazier; P A D'Amore
Journal:  J Cell Sci       Date:  1994-01       Impact factor: 5.285

View more
  15 in total

1.  A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome.

Authors:  Zhi Zeng; Marina Hincapie; Sharon J Pitteri; Samir Hanash; Joost Schalkwijk; Jason M Hogan; Hong Wang; William S Hancock
Journal:  Anal Chem       Date:  2011-05-23       Impact factor: 6.986

2.  Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.

Authors:  Junjiro Yoshida; Hikaru Abe; Takumi Watanabe; Manabu Kawada
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

Review 3.  Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.

Authors:  Sayem Miah; Charles A S Banks; Mark K Adams; Laurence Florens; Kiven E Lukong; Michael P Washburn
Journal:  Mol Biosyst       Date:  2016-12-20

4.  sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.

Authors:  Gema Martin-Manso; Maria J Calzada; Yoshiro Chuman; John M Sipes; Charles P Xavier; Vladimir Wolf; Svetlana A Kuznetsova; Jeffrey S Rubin; David D Roberts
Journal:  Arch Biochem Biophys       Date:  2011-03-21       Impact factor: 4.013

5.  Epidermal growth factor receptor (EGFR) signaling is a key mediator of hormone-induced leukocyte infiltration in the pubertal female mammary gland.

Authors:  Mark D Aupperlee; Yong Zhao; Ying Siow Tan; Jeffrey R Leipprandt; Jessica Bennett; Sandra Z Haslam; Richard C Schwartz
Journal:  Endocrinology       Date:  2014-04-02       Impact factor: 4.736

6.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

7.  Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin.

Authors:  Georges Said; Marie Guilbert; Hamid Morjani; Roselyne Garnotel; Pierre Jeannesson; Hassan El Btaouri
Journal:  Chemother Res Pract       Date:  2012-07-01

Review 8.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

9.  Evaluation of GWAS candidate susceptibility loci for uterine leiomyoma in the multi-ethnic NIEHS uterine fibroid study.

Authors:  Brahim Aissani; Kui Zhang; Howard Wiener
Journal:  Front Genet       Date:  2015-07-14       Impact factor: 4.599

10.  Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density.

Authors:  Jing Zhang; Wei Yang; Duanyun Zhao; Yun Han; Bo Liu; Hua Zhao; Hongbo Wang; Quanzhong Zhang; Guangming Xu
Journal:  Oncol Lett       Date:  2013-10-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.